Adverum Biotechnologies Inc (ADVM) Stock Price, Quote & News

Latest News on ADVM

Mar 31, 2025, 4:01 PM EDT - 2 days ago

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 3, 2025, 4:01 PM EST - 4 weeks ago

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Feb 28, 2025, 4:00 PM EST - 4 weeks ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 25, 2025, 7:00 AM EST - 5 weeks ago

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

Feb 5, 2025, 4:05 PM EST - 2 months ago

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nov 20, 2024, 4:05 PM EST - 4 months ago

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 18, 2024, 1:37 PM EST - 4 months ago

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Nov 15, 2024, 4:05 PM EST - 4 months ago

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Nov 4, 2024, 4:39 PM EST - 5 months ago

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Oct 16, 2024, 8:00 AM EDT - 6 months ago

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Sep 4, 2024, 4:05 PM EDT - 7 months ago

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Aug 2, 2024, 7:00 AM EDT - 8 months ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Jul 17, 2024, 3:35 PM EDT - 9 months ago

Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript

Jul 17, 2024, 2:45 AM EDT - 9 months ago

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

May 9, 2024, 4:05 PM EDT - 11 months ago

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

May 3, 2024, 8:00 AM EDT - 11 months ago

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Feb 28, 2024, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 8, 2024, 7:00 AM EST - 1 year ago

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Feb 5, 2024, 7:45 AM EST - 1 year ago

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

Feb 1, 2024, 5:30 PM EST - 1 year ago

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

Jan 29, 2024, 8:00 AM EST - 1 year ago

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Dec 7, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

Nov 28, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

Nov 9, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Nov 6, 2023, 8:00 AM EST - 1 year ago

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D.

Nov 4, 2023, 5:54 PM EDT - 1 year ago

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

Sep 26, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial

Sep 21, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies to Participate in Upcoming Investor Conferences

Sep 5, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 23, 2023, 2:46 PM EDT - 1 year ago

Adverum: H2 2023 Data Readouts For Wet-AMD Gene Therapy

Aug 21, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer

Aug 14, 2023, 8:00 AM EDT - 1 year ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Aug 10, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results

Jun 12, 2023, 8:00 AM EDT - 1 year ago

Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid

Jun 2, 2023, 8:00 AM EDT - 1 year ago

Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference

May 25, 2023, 6:30 AM EDT - 2 years ago

Adverum Biotechnologies Announces New Executive Leadership Roles

May 18, 2023, 9:00 AM EDT - 2 years ago

Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec's Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

May 18, 2023, 9:00 AM EDT - 2 years ago

Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform

May 11, 2023, 4:05 PM EDT - 2 years ago

Adverum Biotechnologies Reports First Quarter 2023 Financial Results

May 10, 2023, 4:05 PM EDT - 2 years ago

Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference

May 2, 2023, 4:30 PM EDT - 2 years ago

Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD

Apr 23, 2023, 1:00 PM EDT - 2 years ago

Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD

Apr 17, 2023, 4:05 PM EDT - 2 years ago

Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting

Mar 30, 2023, 4:05 PM EDT - 2 years ago

Market Cap	90.91M
Revenue (ttm)	3.60M
Net Income (ttm)	-117.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,254.72%
Debt to Equity Ratio	0.00

Volume	154,400
Avg Vol	169,008
Day's Range	N/A - N/A
Shares Out	20.80M
Stochastic %K	25%
Beta	1.14
Analysts	Strong Sell
Price Target	$29.71